Ambu A/S
CSE:AMBU B
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
88.88
153.05
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Ambu A/S
Ambu A/S
Cash & Cash Equivalents
Ambu A/S
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ambu A/S
CSE:AMBU B
|
Cash & Cash Equivalents
kr615m
|
CAGR 3-Years
113%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Cash & Cash Equivalents
kr1.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Demant A/S
CSE:DEMANT
|
Cash & Cash Equivalents
kr1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
|
V
|
ViroGates A/S
CSE:VIRO
|
Cash & Cash Equivalents
kr7.4m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
Ambu A/S
Glance View
Ambu A/S engages in the development, production, and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The firm markets its products worldwide. The firm operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.
See Also
What is Ambu A/S's Cash & Cash Equivalents?
Cash & Cash Equivalents
615m
DKK
Based on the financial report for Sep 30, 2024, Ambu A/S's Cash & Cash Equivalents amounts to 615m DKK.
What is Ambu A/S's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
39%
Over the last year, the Cash & Cash Equivalents growth was 292%. The average annual Cash & Cash Equivalents growth rates for Ambu A/S have been 113% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
